{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:09:00Z","timestamp":1786752540087,"version":"build-2736575974"},"reference-count":43,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Tirbanibulin 1% ointment is a novel synthetic anti-proliferative agent that inhibits tubulin polymerization. It is approved for treating actinic keratosis (AK) on the face and scalp in adults. It has demonstrated good efficacy, an adequate safety profile and excellent patient adherence in the phase 3 clinical trials, however data about its real-life efficacy and safety are lacking. Here we report the experience of the dermatology unit of the University Hospital of Messina. Materials and Methods: We performed a spontaneous open-label, prospective non-randomized study to assess the effectiveness and safety of tirbanibulin 1% ointment for the treatment of 228 AKs in 38 consecutive patients\u201428 males (73%) and 10 females (26%)\u2014aged between 52 and 92 years (mean age: 72 \u00b1 8.92 years). Results: Total clearance was recorded in 51% of lesions, while partial clearance was recorded in 73% of lesions. An excellent tolerability profile and high compliance rate were observed, with no treatment discontinuation due to the onset of adverse events. Conclusion: Our real-life experience confirms the effectiveness and safety of tirbanibulin ointment for the treatment of AKs.<\/jats:p>","DOI":"10.3390\/medicina60020225","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T08:11:27Z","timestamp":1706515887000},"page":"225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6760-9468","authenticated-orcid":false,"given":"Federica","family":"Li Pomi","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-5145","authenticated-orcid":false,"given":"Mario","family":"Vaccaro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-2265","authenticated-orcid":false,"given":"Giovanni","family":"Pallio","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Rottura","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Irrera","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-8441","authenticated-orcid":false,"given":"Francesco","family":"Borgia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.abd.2019.10.004","article-title":"Actinic Keratoses: Review of Clinical, Dermoscopic, and Therapeutic Aspects","volume":"94","author":"Reinehr","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","article-title":"Guidelines of Care for the Management of Actinic Keratosis","volume":"85","author":"Eisen","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Di Bartolomeo, L., Vaccaro, F., Irrera, N., Borgia, F., Li Pomi, F., Squadrito, F., and Vaccaro, M. (2023). Wnt Signaling Pathways: From Inflammation to Non-Melanoma Skin Cancers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021575"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/0190-9622(91)70113-G","article-title":"A Double-Blind, Vehicle-Controlled Study Evaluating Masoprocol Cream in the Treatment of Actinic Keratoses on the Head and Neck","volume":"24","author":"Olsen","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/jdv.13626","article-title":"Actinic Keratosis: Correlation between Clinical and Histological Classification Systems","volume":"30","author":"Schmitz","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jdv.12848","article-title":"Actinic Keratosis with Atypical Basal Cells (AK I) Is the Most Common Lesion Associated with Invasive Squamous Cell Carcinoma of the Skin","volume":"29","author":"Carrato","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant Transformation of Solar Keratoses to Squamous Cell Carcinoma","volume":"331","author":"Marks","year":"1988","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Balcere, A., Rone Kupfere, M., \u010c\u0113ma, I., and Kr\u016bmi\u0146a, A. (2019). Prevalence, Discontinuation Rate, and Risk Factors for Severe Local Site Reactions with Topical Field Treatment Options for Actinic Keratosis of the Face and Scalp. Medicina, 55.","DOI":"10.3390\/medicina55040092"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-022-00674-3","article-title":"A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions","volume":"23","author":"Catapano","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2021.05.056","article-title":"Guidelines of Care for the Management of Actinic Keratosis: Executive Summary","volume":"85","author":"Eisen","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s13671-019-00265-2","article-title":"Updates on Treatment Approaches for Cutaneous Field Cancerization","volume":"8","author":"Huang","year":"2019","journal-title":"Curr. Dermatol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"T58","DOI":"10.1016\/j.ad.2021.07.016","article-title":"[Translated Article] Tirbanibulin: Review of Its Novel Mechanism of Action and How It Fits into the Treatment of Actinic Keratosis","volume":"113","author":"Gilaberte","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/ajd.14151","article-title":"Effectiveness, Safety and Satisfaction of 1% Tirbanibulin Ointment in the Treatment of Actinic Keratoses: A Prospective Study in Real Clinical Practice","volume":"64","year":"2023","journal-title":"Australas. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kirchberger, M.C., Gfesser, M., Erdmann, M., Schliep, S., Berking, C., and Heppt, M.V. (2023). Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144837"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Campione, E., Rivieccio, A., Gaeta Shumak, R., Costanza, G., Cosio, T., Lambiase, S., Garofalo, V., Artosi, F., Lozzi, F., and Freni, C. (2023). Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses. Pharmaceuticals, 16.","DOI":"10.3390\/ph16121686"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Heppt, M.V., Dykukha, I., Graziadio, S., Salido-Vallejo, R., Chapman-Rounds, M., and Edwards, M. (2022). Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061654"},{"key":"ref_18","first-page":"1218","article-title":"Efficacy, Safety, and Tolerability of 4% 5-Fluorouracil Cream in a Novel Patented Aqueous Cream Containing Peanut Oil Once Daily Compared With 5% 5-Fluorouracil Cream Twice Daily: Meeting the Challenge in the Treatment of Actinic Keratosis","volume":"15","author":"Dohil","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s13555-023-00902-6","article-title":"Severity of Local Skin Reactions with 4% 5-Fluorouracil Plus Emollient versus 4% 5-Fluorouracil Alone in Patients with Actinic Keratosis: A Single-Blind Randomised Trial","volume":"13","author":"Stockfleth","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.36849\/JDD.2020.5123","article-title":"Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis","volume":"19","author":"Hansen","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1684\/ejd.2012.1707","article-title":"Recurrence Rates and Patient Assessed Outcomes of 0.5% 5-Fluorouracil in Combination with Salicylic Acid Treating Actinic Keratoses","volume":"22","author":"Stockfleth","year":"2012","journal-title":"Eur. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical Diclofenac in Hyaluronan Gel for the Treatment of Solar Keratoses","volume":"44","author":"Gebauer","year":"2003","journal-title":"Australas. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% Diclofenac in 2.5% Hyaluronan Gel in the Treatment of Actinic Keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.23736\/S2784-8671.21.07111-5","article-title":"Treatment Adherence with Diclofenac 3% Gel among Patients with Multiple Actinic Keratoses: An Integrated Low-Intensity Intervention Program versus Standard-of-Care","volume":"157","author":"Perino","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_25","first-page":"166","article-title":"Imiquimod 2.5% and 3.75% for the Treatment of Actinic Keratoses: Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies","volume":"13","author":"Swanson","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103620","DOI":"10.1016\/j.pdpdt.2023.103620","article-title":"Photodynamic Therapy for Intergluteal Warts in a Child Affected by Rett Syndrome","volume":"42","author":"Macca","year":"2023","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Borgia, F., Giuffrida, R., Caradonna, E., Vaccaro, M., Guarneri, F., and Cannav\u00f2, S. (2018). Early and Late Onset Side Effects of Photodynamic Therapy. Biomedicines, 6.","DOI":"10.3390\/biomedicines6010012"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2133.2011.10613.x","article-title":"Photodynamic Therapy with BF-200 ALA for the Treatment of Actinic Keratosis: Results of a Multicentre, Randomized, Observer-Blind Phase III Study in Comparison with a Registered Methyl-5-Aminolaevulinate Cream and Placebo","volume":"166","author":"Dirschka","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bjd.14498","article-title":"A Randomized, Double-blind, Phase III, Multicentre Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz\u00ae) vs. Placebo in the Field-directed Treatment of Mild-to-moderate Actinic Keratosis with Photodynamic Therapy (PDT) When Using the BF-Rhodo LED\u00ae Lamp","volume":"175","author":"Reinhold","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2133.2010.09873.x","article-title":"Photodynamic Therapy with BF-200 ALA for the Treatment of Actinic Keratosis: Results of a Prospective, Randomized, Double-Blind, Placebo-Controlled Phase III Study","volume":"163","author":"Szeimies","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized Trial of Four Treatment Approaches for Actinic Keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"adv00358","DOI":"10.2340\/00015555-3690","article-title":"Systematic Literature Review and Network Meta-Analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses","volume":"101","author":"Ezzedine","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/bjd.12343","article-title":"Network Meta-Analysis of the Outcome \u2018Participant Complete Clearance\u2019 in Nonimmunosuppressed Participants of Eight Interventions for Actinic Keratosis: A Follow-up on a Cochrane Review","volume":"169","author":"Gupta","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e12822","DOI":"10.1111\/dth.12822","article-title":"Relative Efficacy of 5-fluorouracil Compared with Other Treatments among Patients with Actinic Keratosis: A Network Meta-analysis","volume":"32","author":"Wu","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jid.2020.06.021","article-title":"Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis","volume":"141","author":"Steeb","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/jdv.15998","article-title":"The More the Better? An Appraisal of Combination Therapies for Actinic Keratosis","volume":"34","author":"Steeb","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","article-title":"Effectiveness of 5-fluorouracil Treatment for Actinic Keratosis\u2013A Systematic Review of Randomized Controlled Trials","volume":"48","author":"Askew","year":"2009","journal-title":"Int. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Steeb, T., Wessely, A., Petzold, A., Schmitz, L., Dirschka, T., Berking, C., and Heppt, M.V. (2021). How to Assess the Efficacy of Interventions for Actinic Keratosis? A Review with a Focus on Long-Term Results. J. Clin. Med., 10.","DOI":"10.3390\/jcm10204736"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e12521","DOI":"10.1111\/dth.12521","article-title":"Erosive Pustular Dermatosis of the Scalp Following Topical Ingenol Mebutate for Actinic Keratoses","volume":"30","author":"Vaccaro","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"omx043","DOI":"10.1093\/omcr\/omx043","article-title":"Topical 5-Fluorouracil Associated Skin Reaction","volume":"2017","author":"Chughtai","year":"2017","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1067\/mjd.2000.107808","article-title":"Immunomodulatory and Pharmacologic Properties of Imiquimod","volume":"43","author":"Sauder","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/CCID.S374122","article-title":"Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action","volume":"15","author":"Schlesinger","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101803","DOI":"10.1016\/j.pdpdt.2020.101803","article-title":"Topical Tacalcitol as Neoadjuvant for Photodynamic Therapy of Acral Actinic Keratoses: An Intra-Patient Randomized Study","volume":"31","author":"Borgia","year":"2020","journal-title":"Photodiagnosis Photodyn. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:50:33Z","timestamp":1760104233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["medicina60020225"],"URL":"https:\/\/doi.org\/10.3390\/medicina60020225","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]}}}